Metoprolol Pharmaclan (Metoprolol Tartrate)

Metoprolol is a selective β1‑adrenergic blocker used in cardiovascular conditions that involve elevated heart rate or pressure.

• Hypertension: lowers systolic and diastolic blood pressure by decreasing cardiac output.
• Angina pectoris: reduces chest pain by lowering myocardial oxygen demand.
• Myocardial infarction: improves post‑MI survival by decreasing workload and arrhythmias.
• Chronic heart failure: enhances left‑ventricular function and reduces hospitalization risk.
• Cardiac arrhythmias: controls ventricular rate in atrial fibrillation and other tachyarrhythmias.

• Metoprolol selectively antagonizes β1‑adrenergic receptors primarily located in cardiac tissue. By blocking catecholamine binding, it diminishes sympathetic stimulation, leading to a slower heart rate, reduced myocardial contractility, and lower stroke volume. The resulting decrease in cardiac output and renin release contributes to lowered arterial pressure and reduced myocardial oxygen consumption, supporting its therapeutic effects in hypertension, angina, arrhythmias, and heart failure.

Metoprolol may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Fatigue: feeling of tiredness or lack of energy.
• Dizziness: light‑headed sensation, especially on standing.
• Cold extremities: reduced blood flow to hands and feet.
• Gastrointestinal upset: nausea or mild abdominal discomfort.
• Bradycardia: slower than normal heart rate.
• Sleep disturbances: insomnia or vivid dreams.

Serious or Rare Side Effects

• Severe bradycardia or heart block requiring medical attention.
• Marked hypotension leading to fainting or shock.
• Bronchospasm in patients with reactive airway disease.
• Depression or mood changes.
• Allergic reactions such as rash, angioedema, or anaphylaxis.

When prescribing Metoprolol, clinicians should consider several precautionary measures to ensure safe use.

• Assess cardiac function: evaluate baseline heart rate and blood pressure before initiation.
• Monitor for bronchospastic disease: use cautiously in patients with asthma or COPD.
• Adjust in renal/hepatic impairment: dose may need modification in severe dysfunction.
• Avoid abrupt discontinuation: taper gradually to prevent rebound tachycardia or hypertension.
• Store at ambient temperature: keep below 25 °C in original container, protect from moisture.

Metoprolol can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Non‑selective β‑blockers: risk of excessive bradycardia.
• Calcium channel blockers (verapamil, diltiazem): enhanced AV‑node blockade.
• CYP2D6 inhibitors (paroxetine, quinidine): increased metoprolol plasma levels.
• Clonidine withdrawal: potential rebound hypertension.
• Insulin or oral hypoglycemics: may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely)

• NSAIDs: may reduce antihypertensive effect.
• Certain antidepressants (sertraline): potential additive bradycardia.
• Diuretics: may enhance hypotensive effect.
• Antithyroid drugs: alter heart‑rate response.
• Digoxin: possible increased plasma concentration.